Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Novartis Pharma N.V., commonly referred to as Novartis, is a leading global healthcare company headquartered in Basel, Switzerland (BE). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has established itself as a key player in the pharmaceutical industry, focusing on innovative medicines, generics, and biosimilars.
With a strong presence in major operational regions including North America, Europe, and Asia, Novartis is renowned for its commitment to research and development. The company’s core products encompass a wide range of therapeutic areas, including oncology, cardiology, and immunology, distinguished by their cutting-edge technology and patient-centric approach.
Recognised for its significant contributions to healthcare, Novartis consistently ranks among the top pharmaceutical companies globally, driven by a robust pipeline and a dedication to improving patient outcomes.
+91 vs industry average
Novartis Pharma N.V.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fruit and Vegetable Products is among the most carbon-intensive industries
The Fruit and Vegetable Products industry has reduced its overall emissions by 19% since 2018
No reported emissions data is available for Novartis Pharma N.V. yet.
Novartis Pharma N.V., headquartered in Belgium (BE), currently does not have specific emissions data available for the most recent year. The company is a current subsidiary of Novartis AG, which cascades its climate commitments and emissions data.
As part of its climate strategy, Novartis AG has set various reduction targets and initiatives that influence Novartis Pharma N.V. These include commitments under the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded to Novartis Pharma N.V. from its parent company. However, specific reduction targets or achievements for Novartis Pharma N.V. have not been detailed.
The absence of direct emissions data highlights the need for ongoing transparency and accountability in corporate climate commitments. Novartis Pharma N.V. is expected to align with the broader sustainability goals set by Novartis AG, focusing on reducing its carbon footprint and contributing to global climate action.
No climate goals have been disclosed for Novartis Pharma N.V. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Novartis Pharma N.V. yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more